RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

Pneumonia is a lung infection caused by bacteria, viruses, fungi, or tuberculosis. Symptoms include fever, cough, chest pain, ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

People in vulnerable groups are offered vaccines against flu, COVID and RSV, the UKHSA said, adding: "Staying at home when ...

Cases of influenza continue to soar across Canada, meanwhile rates of respiratory syncytial virus, or RSV, and COVID-19 are ...

As health officials report a surge of winter viruses, health experts are warning that heart disease symptoms can sometimes ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Research reveals that even low levels of air pollution significantly increase the risk of respiratory infections in adults, ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.